Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program.
SKIN The Journal of Cutaneous Medicine,
[S. l.], v. 6, n. 6, p. s46, 2022. DOI:
10.25251/skin.6.supp.46. DisponÃvel em:
https://skin.dermsquared.com/skin/article/view/1801. Acesso em: 23 apr. 2025.